Nagata Yasushi, Hiraoka Masahiro, Mizowaki Takashi, Narita Yuichiro, Matsuo Yukinori, Norihisa Yoshiki, Onishi Hiroshi, Shirato Hiroki
Division of Radiation Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):343-7. doi: 10.1016/j.ijrobp.2009.02.087.
To recognize the current status of stereotactic body radiotherapy (SBRT) in Japan, using a nationwide survey conducted by the Japan 3-D Conformal External Beam Radiotherapy Group.
The questionnaire was sent by mail to 117 institutions. Ninety-four institutions (80%) responded by the end of November 2005. Fifty-three institutions indicated that they have already started SBRT, and 38 institutions had been reimbursed by insurance.
A total of 1111 patients with histologically confirmed lung cancer were treated. Among these patients, 637 had T1N0M0 and 272 had T2N0M0 lung cancer. Metastatic lung cancer was found in 702 and histologically unconfirmed lung tumor in 291 patients. Primary liver cancer was found in 207 and metastatic liver cancer in 76 patients. The most frequent schedule used for primary lung cancer was 48 Gy in 4 fractions at 22 institutions (52%), followed by 50 Gy in 5 fractions at 11 institutions (26%) and 60 Gy in 8 fractions at 4 institutions (10%). The tendency was the same for metastatic lung cancer. The average number of personnel involved in SBRT was 1.8 radiation oncologists, including 1.1 certified radiation oncologists, 2.8 technologists, 0.7 nurses, and 0.6 certified quality assurance personnel and 0.3 physicists. The most frequent amount of time for treatment planning was 61-120 min, for quality assurance was 50-60 min, and for treatment was 30 min. There were 14 (0.6% of all cases) reported Grade 5 complications: 11 cases of radiation pneumonitis, 2 cases of hemoptysis, and 1 case of radiation esophagitis.
The current status of SBRT in Japan was surveyed.
通过日本三维适形外照射放疗组开展的一项全国性调查,了解立体定向体部放疗(SBRT)在日本的现状。
问卷通过邮件发送至117家机构。截至2005年11月底,94家机构(80%)给予了回复。53家机构表示已开始开展SBRT,38家机构已获得保险赔付。
共治疗了1111例经组织学确诊的肺癌患者。其中,637例为T1N0M0肺癌,272例为T2N0M0肺癌。702例发现有转移性肺癌,291例患者的肺部肿瘤组织学诊断未明确。发现207例原发性肝癌,76例转移性肝癌。原发性肺癌最常用的治疗方案是22家机构(52%)采用的48 Gy分4次照射,其次是11家机构(26%)采用的50 Gy分5次照射和4家机构(10%)采用的60 Gy分8次照射。转移性肺癌的情况也相同。参与SBRT的人员平均数量为1.8名放射肿瘤学家,其中包括1.1名认证放射肿瘤学家、2.8名技术人员、0.7名护士、0.6名认证质量保证人员和0.3名物理学家。治疗计划最常用的时间为61 - 120分钟,质量保证为50 - 60分钟,治疗为30分钟。报告有14例(占所有病例的0.6%)5级并发症:11例放射性肺炎、2例咯血和1例放射性食管炎。
对日本SBRT的现状进行了调查。